All

Algoan, a turnkey solution to meet new regulatory requirements
17 September 2025

Algoan, a turnkey solution to meet new regulatory requirements

Credit institutions, Buy Now, Pay Later providers and brokers, adopt our credit assessment and decision-making tools compliant with the new CCD2 directive.

Read more
YesWeHack completes first-ever acquisition with purchase of Sekost, French cybersecurity audit specialist
9 September 2025

YesWeHack completes first-ever acquisition with purchase of Sekost, French cybersecurity audit specialist

Paris, September 09, 2025 – YesWeHack, the global Bug Bounty and vulnerability management platform, has announced the acquisition of Sekost, an innovative player in the...

Read more
First Patient Dosed In Citryll’s Phase IIA Trial Evaluating CIT-013 In Rheumatoid Arthritis
2 September 2025

First Patient Dosed In Citryll’s Phase IIA Trial Evaluating CIT-013 In Rheumatoid Arthritis

Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), today...

Read more
SumUp Launches Terminal: An All-in-One POS for Growing Businesses
9 July 2025

SumUp Launches Terminal: An All-in-One POS for Growing Businesses

London, 9th July: Global fintech SumUp today launched SumUp Terminal, an all-in-one point of sale (POS) device that directly addresses the challenges faced by growing...

Read more
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe
2 July 2025

MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more
Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
23 June 2025

Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML

60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2).
EO2463 plus R2 was well tolerated in patients with...

Read more
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress
13 June 2025

MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress

The Company, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with...

Read more
The top 50 venture investors in France : Seventure ranked as #7
13 June 2025

The top 50 venture investors in France : Seventure ranked as #7

We mined CB Insights data on top France-based firms to rank them based on their portfolio strength and ability to predict future winners.

Read more
Enterome, raises $19 million to fund clinical development of its OncoMimics™ immunotherapies to treat Follicular Lymphoma
12 June 2025

Enterome, raises $19 million to fund clinical development of its OncoMimics™ immunotherapies to treat Follicular Lymphoma

Enterome, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing.

Read the press release
Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
2 June 2025

Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, will present positive data from its Phase 1/2 clinical study with...

Read more